Say so long to DDMAC as FDA's OPDP levels up

Share this article:
The FDA gave its Office of Medical Policy a long-awaited org chart upgrade, making it a “super office” and giving the department formerly known as the Division of Drug Marketing, Advertising and Communication, or DDMAC, a new acronym: OPDP.

Under the restructure, DDMAC becomes the Office of Prescription Drug Promotion, a level-up that will mean more authority and resources for promotion oversight at the agency. OPDP continues to be led by Tom Abrams and includes a Division of Professional Promotion, led by acting director Catherine Gray, and a Division of Direct-to-Consumer Promotion, led by acting director Robert Dean. Mark Askine will serve as associate director of OPDP and Marci Kiester associate director of operations.

The Office of Medical Policy contains the Office of Prescription Drug Promotion and the Office of Medical Policy Initiatives, which is tasked with “coordinating medical policy regulations and guidances that address the policy and program areas covered by the Super Office,” including supporting the agency's Sentinel Initiative, Clinical Trials Transformation Initiative and Patient Medication Information Initiative. That office will also take in the Patient Labeling Team, formerly part of the Office of Surveillance and Epidemiology, which aims to “promote the safe and effective use of prescription medications by providing accurate and easily understood patient medication information.”

FDA announced the reorg in February, 2010, saying it would recognize the expanded scope of policy and promotion regulation at the agency in recent years.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...